The chemical class termed MAP17 Inhibitors encompasses a range of compounds designed to modulate the activity of MAP17 (PDZK1IP1), a protein implicated in various biological functions and pathways, notably in the progression of certain cancers. These inhibitors operate through diverse mechanisms, targeting signaling pathways and cellular processes associated with MAP17.
In the context of biology, where MAP17 plays a significant role, these inhibitors aim to disrupt the pathways that contribute to growth and metastasis. They may work by modulating key signaling cascades such as the MAPK/ERK pathway, which is crucial in cell proliferation and survival, or by affecting the PI3K/AKT/mTOR pathway, known for its role in regulating cell growth. Some inhibitors in this class might target proteasome activity, thereby affecting the protein degradation mechanisms that can regulate MAP17 levels. Others might interact with epigenetic modifiers, influencing gene expression patterns that govern MAP17 activity. Additionally, inhibitors focusing on kinase activity are included, given the pivotal role of kinases in numerous signaling pathways linked to some progression, where MAP17 is often upregulated. Moreover, this class of inhibitors includes compounds that might impede angiogenesis and tumor metastasis, processes in which MAP17 is believed to play a role. By targeting these mechanisms, the inhibitors aim to affect microenvironments and its interactions with MAP17. The versatility of this chemical class is a reflection of the multifaceted nature of MAP17's involvement in cellular processes. Their development and application are grounded in the understanding of MAP17's biological functions, offering a strategic approach to modulate its activity in various pathological contexts. The inhibitors' efficacy and specificity in targeting MAP17-related pathways make them a focus of interest in the study of MAP17's role in processes. However, the effectiveness and safety of these inhibitors must be thoroughly assessed through experimental and studies to establish their utility.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor that could possibly inhibit MAP17's role in cell proliferation and progression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor that could possibly impact pathways associated with MAP17 in certain progression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could possibly affect pathways involving MAP17, especially in cell survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Known to inhibit mTOR, this could possibly alter cellular pathways involving MAP17. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could possibly modulate protein degradation pathways affecting MAP17. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
An HDAC inhibitor that could possibly influence gene expression and MAP17's activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that could possibly modulate signaling pathways involving MAP17. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
An EGFR inhibitor that could possibly affect pathways in which MAP17 is implicated. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that could possibly affect signaling pathways where MAP17 plays a role. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
A multi-kinase inhibitor that could possibly impact MAP17-involved certain pathways. | ||||||